stockportfolio.pro
Stocks / RAPP vs WGS
RAPP vs WGS
Rapport Therapeutics, Inc. and GeneDx Holdings Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Rapport Therapeutics, Inc. (RAPP) | GeneDx Holdings Corp. (WGS) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $0 | $427.54M |
| Net income (latest FY) | $-111.48M | $-21.02M |
| Revenue growth (5y CAGR) | — | 19.0% |
| Net margin | — | -4.9% |
| Return on equity | -23.0% | -6.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RAPP — free Open WGS — freeFrequently asked questions
Which is bigger, RAPP or WGS?
Rapport Therapeutics, Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, RAPP or WGS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.